Kim A. Margolin, MD
Growing up, Kim Margolin always liked science and math. By middle school and high school, she was reading about nurses and then women doctors and believed that would be her path in life, too.
"My parents are bright but without much higher education and they wanted to see me raise a family. They were, however, very supportive of my choices and passion,” Margolin says, and she was fortunate to have both the career and family fulfilment.
Margolin studied pre-med at University of California, Los Angeles and went on to medical school at Stanford University School of Medicine. Half way through her time there, she knew she wanted to specialize in oncology and immunology. She went to Yale for residency training and back to University of California, San Diego. She then went to the City of Hope Cancer Center in Southern California for fellowships in oncology, hematology, and bone marrow transplant training. She became a clinical investigator at the City of Hope for 25 years, specializing in immunotherapy for melanoma and kidney cancer.
“There is a continuing and growing interest in immunotherapy for melanoma, because melanoma is difficult to treat with more traditional chemotherapy drugs, and many animal studies show benefits with immunotherapy approaches,” Margolin says.
During her career, Margolin served a five-year term on the FDA’s Oncology Advisory Committee, “the most wonderful honor I have experienced in my career,” she says.
She was also part of the American Board of Internal Medicine Oncology Committee where she wrote and developed questions for medical board exam candidates. This proved to be an in-depth process that introduced her to an array of intelligent minds.
In 2010, Margolin will chair the Cancer Education Committee for the American Society of Clinical Oncology. “This is also a big honor for me and a privilege to contribute to cancer education,” she says.
Dr. Margolin joined Seattle Cancer Care Alliance as a Professor at the University of Washington and a member of the Fred Hutchinson Cancer Research Center in October 2008. She also serves as one of the principal investigators for the University’s Institute for Translational Health Sciences. In her limited spare time, she enjoys traveling, photography, skiing, hiking, and reading fiction.
Kim A. Margolin, MDDr. Margolin treats melanoma, kidney cancer, and germ cell cancer. She is particularly interested in clinical trials that provide the newest investigational therapies for her patients.
Patient Care Philosophy:
Because I treat cancers that occur in a younger age group (melanoma in men and women, sometimes in their 20’s, and germ cell cancer, most common in young men between college age and early adulthood), most patients are otherwise healthy and pursuing early career and family activities. The most important aspect of these treatments is assuring that patients and their families are well-informed about the biology of their disease and its treatment, which allows them to place their full trust in my treatment plan.
- Professor, University of Washington School of Medicine
Dr. Margolin’s clinical efforts are in the treatment of melanoma, kidney cancer and germ cell cancer, and she is particularly interested in clinical trials that provide the newest investigational therapies for her patients. Melanoma and kidney cancer are often treated with immunotherapy, including vaccines, cytokines and immune-cell infusions. Germ cell cancer can be treated effectively with high-dose chemotherapy and autologous blood cell support, which is also an area of specialization for Dr. Margolin.
Education And Training
- University of California, Los Angeles
- Stanford University School of Medicine
- Residency: Yale New Haven Hospital in Connecticut
- Fellowship: University of California, San Diego School of Medicine
- IL-2 "SELECT" for Advanced Melanoma
- MK-3475 Versus Chemotherapy for Advanced Melanoma (P08719/MK-3475-002)